Before propensity score matching, differences could be observed between the sorafenib and lenvatinib groups regarding the Barcelona Clinic liver cancer stage, prothrombin, alpha fetoprotein, and blood urea nitrogen levels. The gene discussed is F2; the disease is liver cancer.